01 Identity and provenance
- Accepted binomial
- Gymnema sylvestre
- Common names
- Gurmar
- Family (APG IV)
- Apocynaceae
- Part used
- Leaf
- Verification tier
- Tier 2 · Verified Clinical columns reviewed and a source is on record.
- Reviewer note (2026 audit)
- EFSA risk assessment: PMC7015520 | VERIFIED 2026 - synthetic analogue, application, interactions, side effects and references populated from retrieved primary/regulatory sources (see References). Interaction entries are labelled CLINICAL (case reports or trials in humans) vs THEORETICAL (in-vitro or animal only). Marketed-formulation column intentionally left blank. | INTERACTION
02 Constituent chemistry
| Chemical class | Marker compound | Synthetic analogue in use |
|---|---|---|
| Triterpenoid saponins | Gymnemic acids
Leaf
|
Acarbose, Miglitol (FUNCTIONAL only - inhibition of intestinal glucose absorption). No structural analogue. |
The analogue column is what makes the interaction reasoning tractable: where a constituent has a marketed structural counterpart, the counterpart's interaction profile is the starting hypothesis for the plant.
03 Stated application
- Reported activity
- Adjunct in type 2 diabetes and impaired glucose tolerance. Gymnemic acids inhibit intestinal glucose absorption and transiently abolish sweet taste perception. Also studied for hypolipidaemic and anti-obesity effect.
- Reported adverse effects
- Mild gastrointestinal discomfort (most commonly reported). Hypoglycaemia when combined with glucose-lowering drugs. EFSA review found limited evidence of relevant adverse effects; long-term human safety data lacking. Avoid in pregnancy.
04 Interaction matrix
Source column, verbatim: CLINICAL: antidiabetic drugs - additive hypoglycaemia; this is the best-documented interaction. THEORETICAL: CYP450 inhibition shown in rat liver microsomes only; human relevance not established.
Normalised onto 1 canonical drug class below.
Curated from the reviewed source
| Drug class | Severity | Mechanism type | Provenance | Expected effect | |
|---|---|---|---|---|---|
|
Antidiabetic drugs (insulin, sulfonylureas, biguanides, GLP-1, SGLT2)
Endocrine
|
3Major | PD-additive | curated A | Symptomatic hypoglycaemia, sweating, tremor, confusion; severe events rep… | why ▾ |
Chemistry of this pair. Triterpene and steroidal saponins alter membrane permeability, inhibit platelet aggregation and show weak steroid-receptor affinity. Class mechanism. Hypoglycaemic botanicals act through insulin secretagogue, insulin-sensitising, alpha-glucosidase-inhibiting or glucose-transport routes. Added to a titrated pharmacological regimen the effects summate rather than plateau.
| |||||
Predicted from constituent chemistry
| Drug class | Severity | Mechanism type | Provenance | Expected effect | |
|---|---|---|---|---|---|
|
Antiplatelet agents
Haemostasis
|
3Major | PD-additive | predicted D | Prolonged bleeding time, surgical and post-procedural bleeding, bruising,… | why ▾ |
Chemistry of this pair. Triterpene and steroidal saponins alter membrane permeability, inhibit platelet aggregation and show weak steroid-receptor affinity. Class mechanism. Organosulfur compounds, gingerols, salicylates, ginkgolides and eugenol inhibit thromboxane A2 synthesis, platelet aggregation and PAF-mediated activation, duplicating the pharmacology of aspirin and P2Y12 blockers.
| |||||
|
Hormonal therapy, oral contraceptives and HRT
Endocrine
|
3Major | PK-CYP3A4 induction + PD-oestrogenic | predicted D | Breakthrough bleeding and contraceptive failure; unpredictable effect in … | why ▾ |
Chemistry of this pair. Triterpene and steroidal saponins alter membrane permeability, inhibit platelet aggregation and show weak steroid-receptor affinity. Class mechanism. CYP3A4-inducing botanicals accelerate ethinylestradiol and progestin clearance. Separately, isoflavone, lignan and coumestan phyto-oestrogens bind oestrogen receptors and may add to or compete with prescribed hormones.
| |||||
05 Hazard register
06 Confusable material
No same-genus or shared-common-name entry in the corpus.
07 Mechanism map
Chemistry sorts to the left, pharmacology to the right. Dashed edges are predicted. Drag nodes, scroll to zoom, export at 3× for a figure.
08 Open literature
Abstract-scoped query built from this binomial, its common names and its marker compounds, run live against Europe PMC, PubMed and OpenAlex, then ranked locally against an evidence hierarchy.
09 Isomechanistic neighbours
Species whose interaction profile overlaps this one, ranked by shared severity weight rather than by count — a shared contraindication counts for more than a shared minor signal. Practical use: these are the plants you should not stack with this one, because the mechanisms summate.
| Species | Family | Shared classes | Weight | Jaccard |
|---|---|---|---|---|
| Tribulus terrestris
Gokshura |
Zygophyllaceae | 3 | 1.00 | |
| Achyranthes aspera
Apamarga |
Amaranthaceae | 3 | 1.00 | |
| Sapindus mukorossi
Reetha |
Sapindaceae | 3 | 1.00 | |
| Cheilocostus speciosus
Kebuka |
Costaceae | 3 | 1.00 | |
| Dioscorea villosa
Wild Yam |
Dioscoreaceae | 3 | 1.00 | |
| Dioscorea bulbifera
Air Potato |
Dioscoreaceae | 3 | 1.00 |
10 References and notes
Source column: Khan F et al. Front Pharmacol 2019;10:1223. doi:10.3389/fphar.2019.01223
Khan F et al. Front Pharmacol 2019
10:1223. doi:10.3389/fphar.2019.01223
BibTeX for all 2 records
@article{KhanFetal2019,
title = {Khan F et al. Front Pharmacol 2019},
author = {Khan F et al.},
journal = {Front Pharmacol},
year = {2019},
}
@article{anon2019,
title = {10:1223. doi:10.3389/fphar.2019.01223},
year = {2019},
doi = {10.3389/fphar.2019.01223},
}
Curator notes
No notes yet.
Sign in to add notes and save monographs.